Patheon to Feature API Development and Manufacturing Capabilities at CPHI/ICSE Worldwide

Patheon, the pharmaceutical services business owned by DPx Holdings B.V., will showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPHI/ICSE Worldwide (7–9 October, Paris, France).

At CPHI/ICSE Worldwide, Patheon will introduce its new end-to-end development offering, OneSource, which now provides a single, seamless solution to customers for Phase I through Phase II projects, delivering a simplified process for both drug substance and drug product development. With the launch of OneSource, Patheon will connect its services from drug substance to drug products, focusing on simplicity, speed and uncompromised quality. The deep expertise in development services and large-scale production will enable Patheon to seamlessly integrate all utilised technologies in one, lean process, which will deliver additional customer value. The OneSource offering is led by Lukas Utiger, PhD, who will give a presentation at the Speaker’s Corner at CPHI/ICSE Worldwide on Wednesday, 8 October at 2:00 p.m., to further educate attendees on the full set of offerings available from Patheon.

“After much work, we are pleased to provide customers OneSource, which is available for Phase I through Phase II projects,” said Lukas Utiger, President, DPx Fine Chemicals (formerly DSM Fine Chemicals) and Integrated Offering. “We continue to streamline this offering and have future plans to provide similar simplicity to Phase III through commercial scale capabilities as well. We feel strongly that it is important to bring fast and simple solutions to our customers that really address their needs.”
 

In addition, representatives from Banner Life Sciences, another business unit of DPx Holdings, will feature research and development capabilities, proprietary pharmaceutical technologies and marketing of prescription and over-the-counter and nutritional proprietary products.